WallStSmart

Aethlon Medical Inc (AEMD)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 865252% more annual revenue ($4.97B vs $574,240). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).

AEMD

Hold

39

out of 100

Grade: F

Growth: 6.3Profit: 3.0Value: 6.0Quality: 6.5
Piotroski: 3/9Altman Z: -39.62

DXCM

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMDUndervalued (+26.1%)

Margin of Safety

+26.1%

Fair Value

$2.83

Current Price

$1.53

$1.30 discount

UndervaluedFair: $2.83Overvalued

Intrinsic value data unavailable for DXCM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEMD3 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
4278.0%10/10

Revenue surging 4278.0% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

Areas to Watch

AEMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.11M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AEMD

The strongest argument for AEMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 4278.0% demonstrates continued momentum.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : AEMD

The primary concerns for AEMD are EPS Growth, Market Cap, Profit Margin.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

AEMD profiles as a hypergrowth stock while DXCM is a mature play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.42 — expect wider price swings.

AEMD is growing revenue faster at 4278.0% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (74/100 vs 39/100), backed by strong 20.1% margins and 13.1% revenue growth. AEMD offers better value entry with a 26.1% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aethlon Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?